- Home
- EIIA vs SCLXW Comparison
EIIA vs SCLXW Comparison
Compare EIIA & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EIIA | SCLXW |
|---|---|---|
| Founded | N/A | N/A |
| Country | | United States |
| Employees | N/A | 30 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | EIIA | SCLXW |
|---|---|---|
| Price | $25.24 | $0.14 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 4.1K | 1.9K |
| Earning Date | N/A | 03-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $55,152,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 22.02 |
| 52 Week Low | $24.37 | $0.04 |
| 52 Week High | $26.33 | $0.64 |
Technical Indicators
Market Signals| Indicator | EIIA | SCLXW |
|---|---|---|
| Relative Strength Index (RSI) | 56.78 | 47.41 |
| Support Level | $24.98 | $0.08 |
| Resistance Level | $25.30 | $0.18 |
| Average True Range (ATR) | 0.08 | 0.03 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 100.00 | 46.45 |
Price Performance
Historical ComparisonAbout EIIA Eagle Point Institutional Income Fund
Eagle Point Institutional Income Fund is a closed-end investment company. Its investment objective is to generate high current income, with a secondary objective to generate capital appreciation.
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.